13 insiders reported 14 Form 4 transactions for Jade Biosciences, Inc. (JBIO) over the past 18 months (most recent 2026-02-13). Recent activity: Dahms Bradford D. (Chief Financial Officer) Buy 37,813 shares, Frohlich Tom (Chief Executive Officer) Buy 78,750 shares, Balta Elizabeth (Chief Legal Officer and Corporate Secretary) Buy 28,125 shares, King Andrew James (Chief Scientific Officer & Head of Research and Development) Buy 41,250 shares, Fairmount Funds Management LLC (Director) Buy 1.3M shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-13 | Dahms Bradford D. | Chief Financial Officer | Buy | 37,813 | $0 |
| 2026-02-13 | Frohlich Tom | Chief Executive Officer | Buy | 78,750 | $0 |
| 2026-02-13 | Balta Elizabeth | Chief Legal Officer and Corporate Secretary | Buy | 28,125 | $0 |
| 2026-02-13 | King Andrew James | Chief Scientific Officer & Head of Research and Development | Buy | 41,250 | $0 |
| 2025-10-08 | Fairmount Funds Management LLC | Director | Buy | 1.3M | $12.2M |
| 2025-10-08 | Harwin Peter Evan | Director | Buy | 1.3M | $12.2M |
| 2025-10-08 | Fairmount Healthcare Fund II L.P. | Director | Buy | 1.3M | $12.2M |
| 2025-10-08 | Kiselak Tomas | Director | Buy | 1.3M | $12.2M |
| 2025-10-08 | Fairmount Healthcare Co-Invest IV L.P. | Director | Buy | 1.3M | $12.2M |
| 2025-05-19 | Frohlich Tom | Chief Executive Officer | Buy | 6,000 | $44,400 |
| 2025-04-30 | RA Capital Healthcare Fund LP | 10% Owner | Buy | 1.1M | $0 |
| 2025-04-30 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Buy | 1.1M | $0 |
| 2025-04-30 | Kolchinsky Peter | 10% Owner | Buy | 1.1M | $0 |
| 2025-04-30 | Shah Rajeev M. | 10% Owner | Buy | 1.1M | $0 |
Source: SEC Form 4 filings · as of 2026-02-13